Hyperthermia ablation associated with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: a systematic review and meta-analysis

This article was originally published here

Cancer Med. October 16, 2021. doi: 10.1002 / cam4.4350. Online ahead of print.


BACKGROUND AND OBJECTIVES: Existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID-19 crisis. However, evidence for decision making is lacking in terms of comparison between HA and HATACE. Here, a comprehensive evaluation was performed to compare the efficacy and safety of HATACE with monotherapy.

MATERIALS AND METHODS: Global studies were collected to evaluate the HATACE regimen for HCC due to the practical need for global extrapolation of the application population. Meta-analyzes were performed using RevMan 5.3 software (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark).

RESULTS: Thirty-six studies involving a large sample of 5036 patients were finally included. Compared with HA alone, HATACE produced the advantage of a 5-year overall survival (OS) rate (OR: 1.90; 95% CI: 1.46, 2.46; p

CONCLUSIONS: Compared to TACE alone, HATACE has been shown to be more effective and safer for HCC. Compared to HA alone, HATACE was found to be more effective for small HCC (> 3 cm) with comparable safety. However, the survival benefit of adjuvant TACE in the HATACE regimen was not found for patients with small HCC (≤3 cm).

PMID:34655179 | DO I:10.1002 / cam4.4350

Source link

About Crystal Morrison

Check Also

Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0 / xM0: the survival benefit is biased in favor of partial nephrectomy

This article was originally published here Cancer Med. 2021 November 14. doi: 10.1002 / cam4.4412. …